Skip to main content
Tiziana files IND for oral formulation of drug for NASH, liver disease

An investigational new drug application was filed by Tiziana Life Sciences with the FDA for an early-stage study of enteric-coated capsules of foralumab in healthy volunteers. The drug is being assessed as a treatment for patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Full Story: